

**ANSWERING EDITOR AND REVIEWERS**

**Dear Editor,**

We have answered all the concerns concerning the manuscript 72632 for World Journal of Transplantation. In particular:

The conflict of interest declaration has been enclosed

The audio core tip has been enclosed as mp3 file

English wording has been reviewed by the American Journal Expert (see the enclosed certification)

All others requested files are enclosed

Figures are now in ppt as requested. Only fig 4 that has been drawn by a designer is in Libre Office. If necessary treat it as an image.

You have now the manuscript in two different colors. Black is the original, red answering reviewer's comments

**Reviewer's code:** 03291255

I read with great interest the review article titled, 'Innovative immunosuppression in kidney transplantation: a challenge for unmet needs' by M. Salvadori and A Tsalouchos. On the whole a well written informative article. A few suggestions: Abstract: ABO incompatible to be changed to antibody incompatible transplantation as only HLAi desensitization has been discussed with inclusion of some common treatment against ABMR resulting from ABOi transplant.

**Answer:** In the abstract ABO incompatible has been changed in antibody incompatible transplantation. The repetition protection has been cancelled.

Page 5 – Anti apoptotic strategies. To provide reason for why the RCT was terminated.



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

is there any possibility of pursuing this option in the future?

**Answer:** The RCT was terminated because of lack of documented efficacy.

Pegylated carboxy haemoglobin – 2 line – ‘It also plays roles in protecting against protection against DGF’ – to correct repetition To add the summary of the findings so far

Page 9: Paragraph 2 – Please add the correlation between EBV seronegatives and PTLD in the Belatacept group.

**Answer:** The correlation between EBV seronegatives and PTLD in the Belatacept group has been added with a new reference.

Page 14 Paragraph 1 – Please correct typo Cq1s.

**Answer:** C1qs has been corrected.

Conclusion: 3rd Page 15 Paragraph 3 – Please change ABOi to AIT. Also, please remove ‘living donors’ as AIT includes both deceased and living donor transplants.

**Answer:** In the conclusion AB0 has been changed tom AIT and living donors have been removed.

**Reviewer's code:** 05040165

"Innovative immunosuppression in kidney transplantation: a challenge for unmet needs"

This review aims to summarize available literature on new innovative drugs for kidney transplantation. The review was carefully done. This is a very interesting paper. You did a great job on provide evidence that principal unmet needs are treatment and prevention of delayed graft function, improve the long-term outcomes, desensitization and treatment of acute antibody-mediated rejection. However, there are some flaws, which should be resolved as following. 1. Systematic reviews and meta-analyses are considered to be the highest quality evidence on a research topic because their study design reduces bias and produces more reliable findings. Please add evidence from recent systematic review and meta-analysis. 2. Finally, since I am not a native English user, I did not check for grammatical errors thoroughly. This should be done by an appropriate language reviewer.

**Answer:** As the manuscript concerns new and future drugs systematic review and metaanalyses are not easy to be found. Anyway, three systemic reviews have been added to the manuscript. You will find them in red color.

English wording has been extensively reviewed by American Journal Experts (please find the certification added).

Thanks to the reviewers concerns the manuscript has been improved.

Best regards.

Maurizio Salvadori MD

January 26th, 2022

